ABAnagha Baviskar

Anagha Baviskar

*This is an algorithmically generated author record based on publicly available information.

Anagha Baviskar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Formulation and Evaluation of Butenafine Hydrochloride Incorporated Solid Lipid Nanoparticles from Novel Excipients for the Treatment of Superficial Fungal Infection

    by Anagha Baviskar, Vivekanand Kashid, Sapana Ahirrao, Deepak Bhambere, Manoj Akul

    Objectives: The objective of the present study was to develop natural excipient-based solid lipid nanoparticles (SLN) of butenafine hydrochloride (BUTE) using a modified solvent emulsification technique and to evaluate the competence of aloe vera nanolipidgel in enhancing the penetration of BUTE. Materials and Methods: BUTE-SLNs were prepared using a 23 3 factorial design to correlate the effect of formulation components on the BUTESLN. Particle size, polydispersity index (PDI), zeta potential, entrapment performance, and drug loading were assessed in the formed SLNs. The fabricated BUTE-SLN was evaluated for transmission electron microscopy, fourier transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffraction study studies and revealed the encapsulation of BUTE in lipid in the amorphous state. BUTE-SLN-based aloe vera gel was formulated and evaluated compared with the marketed product with respect to primary skin irritation, hydration, skin permeation, and antifungal activity. Results: The BUTE-SLN aloe vera gel, optimized for its formulation, features excellent slip properties and controlled drug release. DSC and XRD studies confirm its amorphous nature with effective drug entrapment. The gel provides enhanced skin deposition, improved antifungal activity, and reduced irritation. This makes it a cost-effective and innovative alternative to traditional dosage forms. BUTE-SLN promisingly showed no irritation, higher hydrating potential, slow and sustained release, and enhanced antifungal activity. With an aim to target deeper skin strata, minimize the side effects of drugs and symptomatic impact of fungal infection, and shorten the duration of therapy, BUTE-SLN was successfully prepared. The mean particle size and PDI were 261.25 +/- 2.38 nm and 0.268 +/- 0.01, respectively. Conclusion: BUTE-SLN gel offers improved topical delivery of BUTE with significantly higher compatibility and antifungal activity than the marketed formulation.


  • Open Access

    Formulation Development and Evaluation of Floating Tablets of Zolmitriptan

    by Sapana Ahirrao, Deepak Bhambere, Kunal Todkar, Moreshwar Patil, Pallavi Khairnar, Pavan Udavant, Piyushgir Gosavi, Anagha Baviskar

    Zolmitriptan is the antimigraine agent widely used for the treatment of the migraine. It shows the half-life of 2.5 – 3 h which indicate the frequent dosing to achieve proper pharmacological action of the drug. Gastro Retentive Drug Delivery System (GRDDS) is a common approach to decrease the dosing frequency and increase patient compliance, and delivery of drug through such an approach of floating tablet formulation will meet the requirement. This system showed substantial effect on the drug release through floating and swelling properties. The tablets were formulated by using direct compression technique along with hydrophilic polymers and gas generating system. In the preliminary trials, we observed that the tablets were within pharmacopeial limit. % Drug release of the formulations (F1 – F9) was studied up to 6 h and it was found from 52 to 91 %. The cumulative percentage drug release was inversely proportional to polymer concentrations of HPMC K100 M and PVP K 30. The batches follow Higuchi model of drug release which involves the diffusion mechanism. In-vitro dissolution studies showed good percent drug release, which is in accordance with robinson-errikson equation. Good buoyancy for additional 6 h, trailed by the diffusion.